Formosa Laboratories Inc
TWSE:4746
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Formosa Laboratories Inc
Cash from Operating Activities
Formosa Laboratories Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Cash from Operating Activities
NT$1.3B
|
CAGR 3-Years
27%
|
CAGR 5-Years
23%
|
CAGR 10-Years
18%
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Cash from Operating Activities
NT$1.4B
|
CAGR 3-Years
13%
|
CAGR 5-Years
3%
|
CAGR 10-Years
5%
|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Cash from Operating Activities
NT$595.9m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-5%
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Cash from Operating Activities
NT$7.5B
|
CAGR 3-Years
26%
|
CAGR 5-Years
31%
|
CAGR 10-Years
21%
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Cash from Operating Activities
NT$1.8B
|
CAGR 3-Years
13%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
|
C
|
Caliway Biopharmaceuticals Co Ltd
TWSE:6919
|
Cash from Operating Activities
-NT$425.9m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-55%
|
CAGR 10-Years
N/A
|
|
Formosa Laboratories Inc
Glance View
Formosa Laboratories, Inc. engages in the research and development of biotechnology new drugs. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2009-11-27. The firm primarily provides UV-proof active ingredients series products, vitamin D derivative series products, anti-inflammatory analgesic series products, steroid, anti-cancer drugs, cholesterol phosphate binding agents, nuclear magnetic resonance (NMR) reagents, respiratory disease drugs, central nervous system drugs, immune system regulators and weight loss drugs, as well as customized research and development and original equipment manufacturing (OEM) services. The firm distributes its products to Europe, the Americas, Asia and other markets.
See Also
What is Formosa Laboratories Inc's Cash from Operating Activities?
Cash from Operating Activities
1.3B
TWD
Based on the financial report for Dec 31, 2025, Formosa Laboratories Inc's Cash from Operating Activities amounts to 1.3B TWD.
What is Formosa Laboratories Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
18%
Over the last year, the Cash from Operating Activities growth was 81%. The average annual Cash from Operating Activities growth rates for Formosa Laboratories Inc have been 27% over the past three years , 23% over the past five years , and 18% over the past ten years .
